EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats

Maxime Kurtz iD, Virginie Fabrès, Renaud Dumont iD, Valérie Chetboul iD, Sabine Chahory, Vittorio Saponaro, Emilie Trehiou, Camille Poissonnier, Peggy Passavin, Coline Jondeau, Matthieu Bott, Thierry Buronfosse und 1 weitere

Journal of Veterinary Internal Medicine · 2023

DOI: 10.1111/jvim.16741 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2023. Verfasst von Maxime Kurtz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Ecole Nationale Vétérinaire d'Alfort - CHUVA, Service de Médecine Interne, Maisons-Alfort, France. Hauptthemen laut MEDLINE: Cat Diseases, Renal Insufficiency, Chronic, Hyperaldosteronism, Hypertension. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ECVIM-CA Clinical Studies Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In a previous study, telmisartan suppressed aldosterone secretion in healthy cats but not in cats with primary hyperaldosteronism (PHA). Hypotheses Telmisartan suppresses aldosterone secretion in middle-aged healthy cat and cats with diseases that may result in secondary hyperaldosteronism, but not in those with PHA. Animals Thirty-eight cats: 5 with PHA; 16 with chronic kidney disease (CKD), subclassified as hypertensive (CKD-H) or non-hypertensive (CKD-NH); 9 with hyperthyroidism (HTH); 2 with idiopathic systemic arterial hypertension (ISH); and 6 healthy middle-aged cats.

Methods

Prospective, cross-sectional study. Serum aldosterone concentration, potassium concentration, and systolic blood pressure were measured before and 1 and 1.5 hours after PO administration of 2 mg/kg of telmisartan. The aldosterone variation rate (AVR) was calculated for each cat.

Results

No significant difference in the minimum AVR was observed among groups (median [quartile 1 (Q1); quartile 3 (Q3)]: 25 [0; 30]; 5 [−27; −75]; 10 [−6; −95]; 53 [19; 86]; 29 [5; 78]) for PHA, CKD, HTH, ISH, and healthy cats, respectively (P = .05). Basal serum aldosterone concentration (pmol/L) was significantly higher in PHA cats (median [Q1; Q3]: 2914 [2789; 4600]) than in CKD-H cats (median [Q1; Q3]: 239 [189; 577], corrected P value = .003) and CKD-NH cats (median [Q1; Q3]: 353 [136; 1371], corrected P value = .004). Conclusions and Clinical Importance The oral telmisartan suppression test using a single dose of 2 mg/kg telmisartan did not discriminate cats with PHA from healthy middle-aged cats or cats with diseases that may result in secondary hyperaldosteronism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cat DiseasesRenal Insufficiency, ChronicHyperaldosteronismHypertensionCross-Sectional StudiesNephritisAldosteroneHypertension, RenalCatsTelmisartanAnimals

Stichwörter der Autor:innen

adrenaladrenal glandaldosteronecardiologycardiovascularendocrinologyhemodynamicshypertensionhypertrophic cardiomyopathyhypokalemiaretinopathy

Substanzen

TelmisartanAldosterone

Autor:innen und Institutionen

  • Ecole Nationale Vétérinaire d'Alfort - CHUVA, Service de Médecine Interne, Maisons-Alfort, France.
  • Aquivet Clinique Veterinaire - Service de Médecine Interne, Eysines, France.
  • Centre Hospitalier Veterinaire Fregis, Arcueil, France.
  • École Nationale Vétérinaire d'Alfort - CHUVA, Unité de Cardiologie d'Alfort, Maisons-Alfort, France.
  • Ecole Nationale Vétérinaire d'Alfort - CHUVA, Unité d'Ophtalmologie, Maisons-Alfort, France.
  • VetAgro Sup - Service De Biologie Clinique, Marcy-l'Etoile, France.

ORCID-Profile: Maxime Kurtz, Renaud Dumont, Valérie Chetboul, Ghita Benchekroun

Förderung

  • ECVIM-CA Clinical Studies Fund

Zitieren

APA

Kurtz, M., Fabrès, V., Dumont, R., Chetboul, V., Chahory, S., Saponaro, V., Trehiou, E., Poissonnier, C., Passavin, P., Jondeau, C., Bott, M., Buronfosse, T., & Benchekroun, G. (2023). Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16741

Vancouver

Kurtz M, Fabrès V, Dumont R, Chetboul V, Chahory S, Saponaro V, et al. Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats. Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16741

BibTeX
@article{Kurtz2023,
  author = {Kurtz, Maxime and Fabrès, Virginie and Dumont, Renaud and Chetboul, Valérie and Chahory, Sabine and Saponaro, Vittorio and Trehiou, Emilie and Poissonnier, Camille and Passavin, Peggy and Jondeau, Coline and Bott, Matthieu and Buronfosse, Thierry and Benchekroun, Ghita},
  title = {Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2023},
  doi = {10.1111/jvim.16741}
}
Kostenlos starten →